Find Patient Assistance
We can help identify the most appropriate assistance option to help your patient get the Genentech medicines he or she needs.
Patient Assistance Tool
Find the right assistance option for your patients.
Is your patient insured?
Does your patient have commercial insurance?What does this mean?
Has your patient already been referred to a Genentech co-pay card and is either ineligible or no longer receiving assistance?
Has your patient already been referred to a co-pay assistance foundation and is either ineligible for assistance or no longer receiving it?
Is the patient taking XOLAIR for an indicated use, per prescribing information?
Does the patient obtain XOLAIR through 1 of the participating Specialty Pharmacies or receive treatment through a buy and bill office, alternate injection center (AIC) or hospital outpatient department (HOPD)?
XOLAIR Co-pay Card
This program may be able to help your eligible patient's out-of-pocket expenses associated with their XOLAIR® (omalizumab) prescriptions.
Co-pay Assistance Foundations
If patients need help with their medication co-pays, XOLAIR Access Solutions can refer them to a co-pay assistance foundation supporting their disease state.
GATCF helps qualified patients receive their medicine free of charge. To qualify for free medicine from GATCF, patients need to meet specific medical and financial criteria.
Patient Assistance Programs
If you are already aware of the appropriate assistance program for your patient, select the relevant option below:
*Genentech and Novartis Pharmaceuticals Corporation do not influence or control the operations of these co-pay assistance foundations, but XOLAIR Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis. We cannot guarantee co-pay assistance once a patient has been referred by XOLAIR Access Solutions. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.